EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorised Breyanzi (lisocabtagene maraleucel) for additional lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma, as well as med…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mediastinal Neoplasms

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Mediastinal Neoplasms. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 21/11/2025